Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Biotechnology

Healthcare
$7.46 +1.16%

+$0.05 today

Market cap
$587.14M
Beta
0.50
P/E (TTM)
-2.8
EPS (TTM)
-$1.42
52W Low $2.20High $5.42

Volume 1.20M

Average 0.22M

OBIO EBITDA Margin

EBITDA as a percentage of revenue.

Orchestra BioMed Holdings, Inc.NASDAQ: OBIO

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -17981.8%

EBITDA Margin was -17981.8% in Q1 FY2026, down 15830.7 pp from a year earlier. On a trailing-twelve-month basis it was -161.1%, up 2125.8 pp year over year. Over 3 fiscal years it widened by 792.0 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -15717.8% for the fiscal year ending Dec 2026, down from -153.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-17981.8%-18004.8 pp QoQ
Last fiscal yearDec 2025
-153.0%+2148.6 pp YoY
LTMMar 2026
-161.1%+2125.8 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-15830.7 pp-18392076.1 pp-18376245.4 pp
1 year+2148.6 pp-15564.8 pp-17713.4 pp
3 years+792.0 pp-137.8 pp-929.8 pp
5 years+171.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-153.0%
Year-over-year change
+2148.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How OBIO compares with its peers on the latest reported figures

  • OBIO's LTM Mar 2026 EBITDA Margin of -161.1% is the 3rd highest of the 9 companies compared; the peer median is -773.7%.
  • Its year-over-year change of +2125.8 pp is the highest of 7, against a peer median of +156.1 pp.
  • Over three fiscal years its change of +792.0 pp compares with a peer median of -1502.5 pp.
OBIO Competitors Peer median
EBITDA Margin for OBIO and competitors
Company Period LTM level YoY 3-year change
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-67.3% +67.9 pp+30.0 pp
IVVDInvivyd, Inc.LTM Mar 2026-135.5% +244.4 pp—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-161.1% +2125.8 pp+792.0 pp
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026-455.3% +1345.3 pp—
PYXSPyxis Oncology, Inc.LTM Mar 2026-547.9% ——
CRBUCaribou Biosciences, Inc.LTM Mar 2026-999.5% +475.3 pp-608.7 pp
IVAInventiva S.A.FY2025-2858.6% -1048.1 pp-2396.4 pp
TNYATenaya Therapeutics, Inc.LTM Mar 2026-33540.9% ——
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-142957.6% -159600.9 pp-131573.1 pp
EPRXEupraxia Pharmaceuticals Inc.FY2025— ——
TARAProtara Therapeutics, Inc.FY2025— ——
Peer median (excluding OBIO) -773.7%+156.1 pp-1502.5 pp

Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue(782K)3.53M2.76M2.64M33.48M
Cost of Revenue199K322K186K204K190K
Gross Profit(981K)3.21M2.57M2.43M33.29M
Gross Margin125.4%90.9%93.3%92.3%99.4%
Research & Development12.89M21.95M33.82M42.8M58.19M
Selling, General & Admin7.93M13.92M20.26M23.93M26.91M
Operating Expenses20.82M35.87M54.08M66.74M85.1M
Depreciation & Amortization181K222K287K308K327K
EBITDA(21.91M)(33.39M)(48.83M)(60.72M)(51.23M)
EBITDA Margin2801.3%-945.0%-1769.3%-2301.6%-153.0%
Operating Income(21.8M)(32.66M)(51.51M)(64.3M)(51.81M)
Operating Margin2787.6%-924.3%-1866.2%-2437.5%-154.7%
Interest Income050K3.85M3.36M0
Interest Expense927K0001.15M
Other Income / Expenses(1.22M)(951K)2.39M3.28M(894K)
Income Before Tax(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Pre-Tax Margin2943.0%-951.3%-1779.7%-2313.3%-157.4%
Income Tax Expense00000
Net Income(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Net Margin2943.0%-951.3%-1779.7%-2313.3%-157.4%
EPS (Basic)(0.02)(1.32)(1.48)(1.66)(1.38)
EPS (Diluted)(0.02)(1.32)(1.48)(1.66)(1.38)
Weighted Avg Shares20.45M25.47M33.23M36.82M38.39M
Weighted Avg Shares (Diluted)20.45M25.47M33.23M36.82M38.39M

Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Intrinsic Alpha fair value

Locked

Current Price

$7.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.